Introduction
Idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis associated with collagen vascular disorder (PF-CVD) are chronic lung diseases of unknown aetiology which are characterized by the accumulation of neutrophils, eosinophils and mononuclear cells (l-3). These are followed by the progressive deposition of collagen within the interstitium, and subsequent destruction of lung airspace, loss of functional lung units and development of pulmonary fibrosis (4) . Recently, it was reported that hepatocyte growth factor (HGF) in serum is increased in patients with inflammatory lung disease (5) . In the lung HGF is synthesized and secreted by mesenchymal cells, such as macrophages, endothelial cells and fibroblasts (6) . HGF controls proliferation and morphogenesis of epithelial cells (6) . It has recently been revealed that the lung has en endocrine function and produces HGF for the regeneration of injured tissues or organs (7) . HGF also acts as a pulmotrophic factor in lung regeneration after acute lung injury (7) , and is a potential paracrine growth factor for rat alveolar type II cells in primary culture (6) . Therefore, it has been hypothesized that HGF might play an important role in regulating the growth of lung epithelium, and in the regeneration of the lung as a paracrine or endocrine factor in pulmonary fibrosis. However, the role of HGF in patients with pulmonary fibrosis still remains unclear. In order to evaluate correlations between HGF and other factors, the following parameters were measured in patients with IPF and patients with PF-CVD.
Methods

STUDY POPULATION
Twenty-one patients with a diagnosis of pulmonary fibrosis in Kagawa Medical Hospital (613 beds) and Matsuyama Citizen Hospital (538 beds) were studied from 1990 to 1996. Of the 21 patients, 14 had IPF and seven had PF-CVD (three had rheumatoid arthritis, three had dermatomyositis and one had Sjogren syndrome). Median age of the patients was 69 years with a range of 4486 years (13 men and eight women). There were 14 non-smokers four ex-smokers and three current smokers. The diagnoses were made by clinical, radiological, physiological and histological grounds. The criteria used included: history of exertional dyspnoea and cough, fine crackles on physical examination, compatible findings on the chest radiograph (diffuse basal reticulonodular shadows), physiological abnormalities of restrictive lung defect including decreased diffusing capacity, and abnormal PaO, at rest and/or with exertion. Histological confirmation was obtained in call cases by open lung biopsy. The histology of all patients with PF-CVD were usual interstitial pneumonia (UIP) pattern. In all patients, high-resolution computed radiographic scanning of the lungs (HRCT) was performed (1, 8) . All patients received no immunosuppressive treatment such as corticosteroid or cyclophosphamide. Twenty-one normal subjects (15 non-smokers and six smokers) were also studied (average age 55 years). All subjects had no history of lung disease, no clinical findings suggesting lung disease, and no liver and renal dysfunction. They all had normal chest X-rays and their pulmonary function test results were within a normal limit. Ten cases (seven smokers and three smokers) of 21 normal subjects could be studied for bronchoalveolar lavage (BAL). The protocols were approved by the institutional review board for human studies, and informed written consent was obtained.
BLOOD SAMPLES
Peripheral venous blood samples with and without ethylenediaminetetraacetic acid (EDTA) were obtained before breakfast. After centrifugation at 1000 g for 10 min at 4°C the serum was frozen and stored at -70°C until used. Arterial blood samples were analysed for PaO, and PCO, using a blood gas analyser.
BRONCHOALVEOLAR LAVAGE
After the upper airway was anaesthetized with topical lignocaine, a flexible fibre-optic bronchoscope was wedged into the lower respiratory tract under visualization. To sample the lower respiratory tract, BAL was performed by infusing three 50 ml aliquots of sterile saline at the site of the anterior segment of the right lower lobe. The last two aliquots were saved for evaluation. The fluid was filtered through gauze, and cells were separated from alveolar lavage fluid by centrifugation (300g for 10 min). BAL fluid (BALF) was frozen and stored at -70°C until used.
MEASUREMENT OF HGF LEVELS IN SERUM AND BALF
HGF was measured by enzyme-linked immunosorbent assay (ELISA) with monoclonal and polyclonal antibodies against human HGF (Otsuka Assay Laboratories, Tokushima, Japan). This assay was calibrated using standard solutions of known HGF concentrations. The lower detection limit of this assay was 0.02 ng ml -'. When HGF levels in BALF were under the detection limit in a patient group, the BALF was concentrated five times using the lyophilization method. Data were expressed as mean values from duplicate determinations. Peripheral blood samples were measured for white blood cell counts and erythrocyte sedimentation rate (ESR). The serum samples were analysed for HGF, elastase, C-reactive protein (CRP), lactase dehydrogenase (LDH) and Immunoglobulin G (IgG). The BALF samples were analysed for HGF, elastase, LDH, carcinoembryonic antigen (CEA), CA19-9, squamous cell carcinoma related antigen (SCC), IgG, IgA, albumin and cellular profiles. These tumour markers were measured by radioimmunoassay. Elastase levels in serum and BALF were determined by using an ELISA kit purchased from Merck (Diagnostica Merck, Darmstadt, Germany). To exclude the effect of dilution, data in BALF were corrected by albumin (divided each datum by albumin). As a pulmonary function test, %VC and FEVl.O% were measured in all patients.
HGF in sera and BALF were also measured in normal subjects, and compared with the results of patients with pulmonary fibrosis. In patients with pulmonary fibrosis, correlations between each parameters were evaluated, and the difference of the HGF levels in serum and BALF were compared between non-smokers as well as ex-smokers and current smokers.
STATISTICAL METHODS
Data are expressed as means & standard error of the mean. Mann-Whitney U-test was used for the comparison between individual groups. Correlations were evaluated by the Pearson's correlation coefficient, and Fisher's Y to z method was used to calculate the P values. Statistical significance was assumed for P<O.O5. patients with pulmonary fibrosis (72 f 17 ng g-' albumin) were also significantly elevated as compared with normal subjects (under the detection limit) (WO.01). Correlations between HGF levels in sera and other parameters in patients with pulmonary fibrosis are shown in 
Results
Discussion
It has been reported that HGF is an important growth factor for various epithelial cells, and it has a mitogenic, motogenic, morphogenic and tumour suppressive function (9) (10) (11) (12) . In addition, it has been reported that HGF is shown to be a mitogen for the rat alveolar type II cells in primary culture (6) . Previously, the present authors have shown that serum HGF concentration in patients with pneumonia was significantly higher as compared with patients without pneumonia, and the increase of serum HGF followed shortly after the onset of inflammation (13) . This suggests that HGF has a important role in regeneration of the lung following acute lung injury, and HGF could be an indicator of lung repair after lung damage in patients with lung disease (13) . In addition, Maeda et al. have also suggested that serum HGF levels increase in inflammatory lung diseases including interstitial pneumonitis, and HGF levels in the surviving patients decrease rapidly with treatment (5) . In the present study, the increase of HGF in sera was confirmed, and the increase of HGF levels in BALF of patients with pulmonary fibrosis was demonstrated. There was no significant difference of HGF levels in sera or BALF between patients with IPF and patients with PF-CVD. Therefore, data from both patients with IPF and patients with PF-CVD were handled together.
In addition, the correlations between HGF and other parameters in patients with pulmonary fibrosis were evaluated. Although Maeda et al. reported that there is no significant correlation between serum HGF and CRP as well as PaO, (5) , HGF levels in sera correlated significantly with elastase levels in sera and CRP, and correlated negatively with PaO, in the present study. This controversy might be explained by the difference of patient selection (they included hypersensitivity pneumonitis and bacterial pneumonia) (5) .
Correlation between HGF in sera and elastase in sera seemed to be very interesting. As HGF is believed to play an important role in the process of lung regeneration, HGF in sera might increase in response to the excess of elastase which is considered to be a destructive factor.
Tumour markers are believed to be released from lung epithelial cells, and secretory IgA is produced by the epithelial cells of the respiratory tract (14) . If epithelial cells are damaged by destructive factor such as neutrophil elastase (15) , it is possible to consider that LDH, CEA, CAl9-9, SCC and IgA are released from epithelial cells and represent the degree of epithelial cell damage. In addition, followed by the epithelial cell damage, HGF might act on type II cells to regenerate the epithelium.
As the detection limit of the HGF assay was 0.02 ng ml ~ ', it is frequently difficult to detect HGF in BALF. Although the BALF was concentrated five times using the lyophilization method. almost eight patients with pulmonary fibrosis have undetectable levels of HGF in their bronchial alveolar fluid. However, if BALF was concentrated more than five times, it may be possible to demonstrate the difference of BALF HGF levels between patients with pulmonary fibrosis and normals.
The ratio of HGF/albumin in BALF divided by serum HGF/serum albumin concentration was more than 1.0. In addition, the authors also demonstrated that HGF/albumin in BALF correlated strongly with total number of alveolar macrophagelalbumin.
These results suggested that most HGF in the alveolus might be produced locally by alveolar macrophages. In fact, the production of HGF by alveolar macrophage has been reported very recently using i/z situ hybridization (16) . Interestingly, HGF levels in sera of smokers with pulmonary fibrosis were significantly higher when compared with non-smokers and ex-smokers. As smoking is one of the poor prognostic factors of IPF, this evidence may also explain why HGF responded to the lung injury caused by smoking. An analysis of the effects of smoking on HGF in a much larger number of persons will be required in the future.
The authors also evaluate the clinical significance of HGF as a prognostic factor. However, the follow-up period of the study population was not enough; no results have been obtained at present.
In conclusion, these data demonstrated: (i) HGF in serum and BALF was increased in patients with pulmonary fibrosis; and (ii) HGF in serum and BALF correlated with clinical parameters in pulmonary fibrosis. These results suggest that HGF may play a role in the process of lung injury and repair in pulmonary fibrosis.
